Blog
Animal Experimentation Reduction Methods and Best Practices
Animal experimentation reduction techniques offer a variety of partial solutions to the enduring controversial issue of animal use in scientific research. In the United States alone, The Humane Society estimates that over 50 million animals are used in experiments annually.
Animal Experimentation Reduction Methods and Best Practices
Animal experimentation reduction techniques offer a variety of partial solutions to the enduring controversial issue of animal use in scientific research. In the United States alone, The Humane Society estimates that over 50 million animals are used in experiments annually.
What Is the Translational Gap and How Do You Close It?
Drug discovery has a translatability problem. The National Institutes of Health (NIH) once famously reported that for every drug that receives FDA approval, another 1,000 fail. In drug development, translatability refers to the basic principle of taking scientific findings from a laboratory setting and successfully translating them as therapeutic patient treatments in a clinical setting. This is sometimes also referred to as the bench-to-bedside process.
What Is the Translational Gap and How Do You Close It?
Drug discovery has a translatability problem. The National Institutes of Health (NIH) once famously reported that for every drug that receives FDA approval, another 1,000 fail. In drug development, translatability refers to the basic principle of taking scientific findings from a laboratory setting and successfully translating them as therapeutic patient treatments in a clinical setting. This is sometimes also referred to as the bench-to-bedside process.
.jpeg)
FDA Modernization Act & What It Means for VeriSIM Life
The FDA Modernization Act strikes out the language referencing animal testing and introduces, in its place, “non-clinical tests” such as those made possible by AI and data modeling. This change has seen a level of bipartisan support rarely witnessed in legislation today, and it is a critical milestone in the history of R&D in that it supports use of simulation and predictive technologies to increase efficiency and candidate success.VeriSIM Life has been ahead of the curve in recognizing these advantages for five years and counting, pioneering the way towards this inevitable industry change by using technology to help clients increase the efficacy of preclinical testing while taking measures towards “de-risking” the process.
FDA Modernization Act & What It Means for VeriSIM Life
The FDA Modernization Act strikes out the language referencing animal testing and introduces, in its place, “non-clinical tests” such as those made possible by AI and data modeling. This change has seen a level of bipartisan support rarely witnessed in legislation today, and it is a critical milestone in the history of R&D in that it supports use of simulation and predictive technologies to increase efficiency and candidate success.VeriSIM Life has been ahead of the curve in recognizing these advantages for five years and counting, pioneering the way towards this inevitable industry change by using technology to help clients increase the efficacy of preclinical testing while taking measures towards “de-risking” the process.
Biosimulation in Depth: A Detailed Guide
Biosimulation, which uses computer simulations of biological processes to predict the behavior of biological systems, is on a significant growth trajectory – thanks in part to the FDA’s strong recommendation for adopting biosimulation, an overall increase in predictive biosimulation in the research and development (R&D) process, and the recent use of biosimulation platforms for the development of COVID-19 vaccines. Now, as pharmaceutical and biotech companies continue to invest in artificial intelligence (AI)-enabled tools and technologies, we should expect to see even more widespread adoption of biosimulation across drug discovery and development.
Biosimulation in Depth: A Detailed Guide
Biosimulation, which uses computer simulations of biological processes to predict the behavior of biological systems, is on a significant growth trajectory – thanks in part to the FDA’s strong recommendation for adopting biosimulation, an overall increase in predictive biosimulation in the research and development (R&D) process, and the recent use of biosimulation platforms for the development of COVID-19 vaccines. Now, as pharmaceutical and biotech companies continue to invest in artificial intelligence (AI)-enabled tools and technologies, we should expect to see even more widespread adoption of biosimulation across drug discovery and development.
.png)
Introducing AtlasGEN™ Novel Drug Designer
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
